PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11504680-4	2001	Pretreatment with 100 ng/ml of FK506 (a PP2B inhibitor) but not with the PP1 and PP2A inhibitors calyculin A or okadaic acid potentiated the thrombin-induced increase in PKC phosphotransferase activity.	Tacrolimus	31-36	coagulation factor II, thrombin	Bos taurus	141-149	
19235203-8	2009	Treatment of BPAEC with Cn inhibitors (cyclosporin A and FK506) hindered recovery of the cells from thrombin-induced EC dysfunction.	Tacrolimus	57-62	coagulation factor II, thrombin	Bos taurus	100-108	
11504680-5	2001	FK506 also potentiated thrombin-induced PKC-alpha but not PKC-beta phosphorylation.	Tacrolimus	0-5	coagulation factor II, thrombin	Bos taurus	23-31	
11504680-6	2001	FK506 but not calyculin A or okadaic acid inhibited recovery from the thrombin-induced decrease in transendothelial resistance.	Tacrolimus	0-5	coagulation factor II, thrombin	Bos taurus	70-78	
11504680-8	2001	Downregulation of PKC with phorbol 12-myristate 13-acetate rescued the FK506-mediated inhibition of recovery, which was consistent with the finding that the thrombin-induced phosphorylation of PKC-alpha was reduced during the recovery phase.	Tacrolimus	71-76	coagulation factor II, thrombin	Bos taurus	157-165